Hikma Pharmaceuticals Plc (HIK) - Financial and Strategic SWOT Analysis Review

Date: June 6, 2017
Pages: 56
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: H9CD916A6EAEN
Leaflet:

Download PDF Leaflet

Hikma Pharmaceuticals Plc (HIK) - Financial and Strategic SWOT Analysis Review
Hikma Pharmaceuticals Plc (HIK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Hikma Pharmaceuticals Plc (Hikma) is a pharmaceutical company which undertakes the development, manufacturing and marketing of branded and non-branded generics and in-licensed products. The company specializes in the therapeutic areas of cardiovascular and diabetes, central nervous system, oncology, dermatology, genitourinary system, hormones and respiratory system, among others. It offers generics in various dosage forms including tablets, capsules, solutions and suspensions. Hikma markets its products across Europe, the US, the Middle East and North Africa region. It has manufacturing facilities in the US, Portugal, Germany, Jordan, Algeria, Sudan, Saudi Arabia, Egypt, Tunisia and Morocco. Hikma is headquartered in London, the UK.

Hikma Pharmaceuticals Plc Key Recent Developments

May 03,2017: Hikma Changes Registered Office
Mar 15,2017: Hikma delivers a solid financial performance in 2016 and makes significant strategic progress Strong growth in revenue and core operating profit in constant currency
Nov 10,2016: Hikma Pharmaceuticals: Trading Update
Sep 20,2016: Hikma Pharmaceuticals: Board Appointment and Succession
Aug 24,2016: Hikma delivers solid first half performance and reiterates full year revenue guidance of $2.0 billion to $2.1 billion

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
SECTION 1 - ABOUT THE COMPANY

Hikma Pharmaceuticals Plc - Key Facts
Hikma Pharmaceuticals Plc - Key Employees
Hikma Pharmaceuticals Plc - Key Employee Biographies
Hikma Pharmaceuticals Plc - Major Products and Services
Hikma Pharmaceuticals Plc - History
Hikma Pharmaceuticals Plc - Company Statement
Hikma Pharmaceuticals Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture

SECTION 2 – COMPANY ANALYSIS

Hikma Pharmaceuticals Plc - Business Description
Hikma Pharmaceuticals Plc - Corporate Strategy
Hikma Pharmaceuticals Plc - SWOT Analysis
SWOT Analysis - Overview
Hikma Pharmaceuticals Plc - Strengths
Hikma Pharmaceuticals Plc - Weaknesses
Hikma Pharmaceuticals Plc - Opportunities
Hikma Pharmaceuticals Plc - Threats
Hikma Pharmaceuticals Plc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Hikma Pharmaceuticals Plc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

May 03, 2017: Hikma Changes Registered Office
Mar 15, 2017: Hikma delivers a solid financial performance in 2016 and makes significant strategic progress Strong growth in revenue and core operating profit in constant currency
Nov 10, 2016: Hikma Pharmaceuticals: Trading Update
Sep 20, 2016: Hikma Pharmaceuticals: Board Appointment and Succession
Aug 24, 2016: Hikma delivers solid first half performance and reiterates full year revenue guidance of $2.0 billion to $2.1 billion
May 24, 2016: Michael Raya, CEO of West-Ward Pharmaceuticals, Hikma’s wholly-owned subsidiary in the US, joins GPhA Board
Mar 16, 2016: Hikma Pharmaceuticals Preliminary Results
Feb 22, 2016: Hikma Appoints John Castellani to Board of Directors

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Hikma Pharmaceuticals Plc, Key Facts
Hikma Pharmaceuticals Plc, Key Employees
Hikma Pharmaceuticals Plc, Key Employee Biographies
Hikma Pharmaceuticals Plc, Major Products and Services
Hikma Pharmaceuticals Plc, History
Hikma Pharmaceuticals Plc, Subsidiaries
Hikma Pharmaceuticals Plc, Joint Venture
Hikma Pharmaceuticals Plc, Key Competitors
Hikma Pharmaceuticals Plc, Ratios based on current share price
Hikma Pharmaceuticals Plc, Annual Ratios
Hikma Pharmaceuticals Plc, Annual Ratios (Cont.1)
Hikma Pharmaceuticals Plc, Annual Ratios (Cont.2)
Hikma Pharmaceuticals Plc, Interim Ratios
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Hikma Pharmaceuticals Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Hikma Pharmaceuticals Plc, Performance Chart (2012 - 2016)
Hikma Pharmaceuticals Plc, Ratio Charts
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017

COMPANIES MENTIONED

Teva Pharmaceutical Industries Ltd
Sandoz International GmbH
Novartis Pharmaceuticals UK Ltd
Napp Pharmaceuticals Ltd
Lannett Company Inc
Skip to top


Ask Your Question

Hikma Pharmaceuticals Plc (HIK) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: